Lv4
450 积分 2025-07-07 加入
Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody that targets interleukin-17A, in healthy participants and patients with moderate-to-severe plaque psoriasis
6个月前
已完结
Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events
11个月前
已完结
A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis
1年前
已完结
Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study
1年前
已完结
皖公网安备34019202002308
